Saudi Pharmaceutical Journal (Feb 2020)

Mucoadhesive buccal film of almotriptan improved therapeutic delivery in rabbit model

  • Anroop B. Nair,
  • Bandar E. Al-Dhubiab,
  • Jigar Shah,
  • Shery Jacob,
  • Vismay Saraiya,
  • Mahesh Attimarad,
  • Nagaraja SreeHarsha,
  • Sabah H. Akrawi,
  • Tamer M. Shehata

Journal volume & issue
Vol. 28, no. 2
pp. 201 – 209

Abstract

Read online

Administration of almotriptan as an oral therapy is largely limited because of poor aqueous solubility and rather low bioavailability. The aim of present investigation was to formulate oral mucoadhesive film of almotriptan to improve the drug delivery and desired therapeutic effects. Placebo films (F1-F8) were prepared by varying the concentrations of Proloc 15 (7.5-15% w/v) and Eudragit RL 100/RS 100 (15-30% w/v) polymers. Physicomechanical and pharmaceutical characteristics of drug loaded films (FA1-FA4) were examined. Selected FA4 film was evaluated in vivo by assessing the pharmacokinetic profile and compared with oral therapy in rabbits. FA1-FA4 films exhibited excellent physicomechanical properties and rapid hydration. A biphasic and considerably greater drug release (p 2 folds, p < 0.0001) by FA4 film as compared to oral (control). In general, the data established the potential of FA4 film to improve the therapeutic delivery of almotriptan and offers a promising option in migraine therapy. Keywords: Buccal film, Proloc, Rabbits, Release, Eudragit, In vivo